Hyperkalemia	hyperkalemia	O	DISEASE	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
sulindac	sulindac	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

Hyperkalemia	hyperkalemia	O	DISEASE	OTHERS	I
has	has	O	O	O	O
recently	recently	O	O	O	O
been	been	O	O	O	O
recognized	recognized	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
complication	complication	O	O	O	O
of	of	O	O	O	O
nonsteroidal	nonsteroidal	O	O	O	O
antiinflammatory	antiinflammatory	O	O	O	O
agents	agents	O	O	O	O
(	(	O	O	O	O
NSAID	nsaid	O	O	OTHERS	I
)	)	O	O	O	O
such	such	O	O	O	O
as	as	O	O	O	O
indomethacin	indomethacin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Several	several	O	O	O	O
recent	recent	O	O	O	O
studies	studies	O	O	O	O
have	have	O	O	O	O
stressed	stressed	O	O	O	O
the	the	O	O	O	O
renal	renal	O	O	O	O
sparing	sparing	O	O	O	O
features	features	O	O	O	O
of	of	O	O	O	O
sulindac	sulindac	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
owing	owing	O	O	O	O
to	to	O	O	O	O
its	its	O	O	O	O
lack	lack	O	O	O	O
of	of	O	O	O	O
interference	interference	O	O	O	O
with	with	O	O	O	O
renal	renal	O	O	O	O
prostacyclin	prostacyclin	O	O	OTHERS	I
synthesis	synthesis	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
describe	describe	O	O	O	O
4	4	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
whom	whom	O	O	O	O
hyperkalemia	hyperkalemia	O	DISEASE	OTHERS	I
ranging	ranging	O	O	O	O
from	from	O	O	O	O
6.1	6.1	O	O	O	O
to	to	O	O	O	O
6.9	6.9	O	O	O	O
mEq/l	meq/l	O	O	O	O
developed	developed	O	O	O	O
within	within	O	O	O	O
3	3	O	O	O	O
to	to	O	O	O	O
8	8	O	O	O	O
days	days	O	O	O	O
of	of	O	O	O	O
sulindac	sulindac	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
all	all	O	O	O	O
of	of	O	O	O	O
them	them	O	O	O	O
normal	normal	O	O	O	O
serum	serum	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
levels	levels	O	O	O	O
reached	reached	O	O	O	O
within	within	O	O	O	O
2	2	O	O	O	O
to	to	O	O	O	O
4	4	O	O	O	O
days	days	O	O	O	O
of	of	O	O	O	O
stopping	stopping	O	O	O	O
sulindac	sulindac	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

As	as	O	O	O	O
no	no	O	O	O	O
other	other	O	O	O	O
medications	medications	O	O	O	O
known	known	O	O	O	O
to	to	O	O	O	O
effect	effect	O	O	O	O
serum	serum	O	O	O	O
potassium	potassium	CHEMICALS	O	OTHERS	I
had	had	O	O	O	O
been	been	O	O	O	O
given	given	O	O	O	O
concomitantly	concomitantly	O	O	O	O
,	,	O	O	O	O
this	this	O	O	O	O
course	course	O	O	O	O
of	of	O	O	O	O
events	events	O	O	O	O
is	is	O	O	O	O
suggestive	suggestive	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
cause-and-effect	cause-and-effect	O	O	O	O
relationship	relationship	O	O	O	O
between	between	O	O	O	O
sulindac	sulindac	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
hyperkalemia	hyperkalemia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

These	these	O	O	O	O
observations	observations	O	O	O	O
indicate	indicate	O	O	O	O
that	that	O	O	O	O
initial	initial	O	O	O	O
hopes	hopes	O	O	O	O
that	that	O	O	O	O
sulindac	sulindac	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
not	not	O	O	O	O
be	be	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
adverse	adverse	O	O	O	O
renal	renal	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
other	other	O	O	O	O
NSAID	nsaid	O	O	OTHERS	I
are	are	O	O	O	O
probably	probably	O	O	O	O
not	not	O	O	O	O
justified	justified	O	O	O	O
.	.	O	O	O	O

